Does IQOS produce fewer toxins than combustible cigarettes under FDA?

Question

Accepted Answer

IQOS Produces Fewer or Lower Levels of Some Toxins Than Combustible Cigarettes, According to FDA Determination

The US Food and Drug Administration (FDA) has authorized Philip Morris International's heated tobacco product, IQOS, for sale in the United States, deeming it "appropriate for the protection of public health." This decision was based on the finding that IQOS products generate "fewer or lower levels of some toxins than combustible cigarettes." While the FDA's review indicated that the products do not demonstrate a reduction in long-term disease risks, it concluded that smokers who completely switch to IQOS will experience reduced toxic exposures, likely leading to a lower risk of tobacco-related diseases.
Reduced Toxin Exposure Identified by FDA

The FDA's assessment highlighted that IQOS, which heats tobacco-filled sticks to produce an aerosol containing nicotine, results in a reduction in toxicant exposure compared to traditional combustible cigarettes. This finding was a key factor in the agency's determination that authorizing the device for sale was in the public interest. The agency's review specifically noted that smokers switching entirely to IQOS would benefit from these reduced exposures, with a probable decrease in the likelihood of developing tobacco-related illnesses.
Limited Long-Term Disease Risk Reduction Demonstrated

Despite the identification of reduced toxic exposures, the FDA's review of Philip Morris's studies did not demonstrate a reduction in long-term disease risks associated with IQOS use. However, the agency's conclusion emphasized that the likely consequence of reduced toxic exposure for complete switchers is a lessened risk of disease. This nuanced finding acknowledges potential benefits while maintaining that definitive long-term health risk reduction has not yet been proven through the submitted studies.
Target Demographic and Youth Uptake Data

The FDA identified current cigarette smokers as the demographic most likely to adopt IQOS. Furthermore, data gathered from markets where IQOS is already available, specifically Italy and Japan, indicated "low uptake by youth and current non-smokers." This suggests that the product's adoption has primarily been among existing adult smokers, with limited evidence of appeal to younger individuals or those who do not currently use tobacco products.

Reading history

Hide →

This history is cleared when the page is closed.

Does IQOS produce fewer toxins than combustible cigarettes under FDA?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends